Page 1

Exhibit 99.1 BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate _ Update - Management to host a call today at 8:00 am ET NEW YORK , Sept. 10 , 2021 - BeyondSpring Inc. ( the “ Company ” or “ BeyondSpring ” ) ( NASDAQ : BYSI ) , a global biopharmaceutical company focused on the development of innovative cancer therapies , today announced its financial results for the second quarter ended June 30 , 2021 and provided an update on recent corporate events . " We had a very productive first half of 2021. Importantly , we were thrilled to announce positive data from our registrational trial of plinabulin in 2 nd / 3 rd line NSCLC , which showed significant improvement in overall survival , especially the doubling of 2 - year and 3 - year survival in the plinabulin and docetaxel arm vs. docetaxel alone . This underscores plinabulin's immune durable anti - cancer benefit , which could be the gateway for its development in multiple cancer indication in triple IO combos . With the significant survival benefit and significant reduction in severe neutropenia of chemotherapy , we expect that plinabulin's optimum profile for patient's need is just beginning to be revealed . These data set the stage for multiple near - term catalysts over the next 6-12 months , " said Dr. Lan Huang , co - founder , chairwoman and chief executive officer of BeyondSpring . " Our commercial teams are very busy preparing for the potential near - term commercial launch of plinabulin in our first indication in the U.S. At the same time , we have strategically positioned plinabulin for commercial success in Greater China by partnering with Hengrui , the leading oncology R & D and commercial company in China with great synergy in its pipeline with plinabulin . We believe we are truly on the cusp of unlocking the tremendous potential of plinabulin to help many patients in need , " Dr. Huang continued . Recent Clinical and Corporate Highlights . DUBLIN - 3 Study ( 2 nd / 3 rd line NSCLC - EGFR wild type , a global , single - blinded randomized active controlled registrational study , Plinabulin + Docetaxel vs. Docetaxel alone , primary endpoint : Overall Survival ) : Announced positive topline results of plinabulin in combination with docetaxel for the treatment of 2 nd / 3 rd line non - small cell lung cancer ( NSCLC ) with EGFR wild type . The data showed that , compared to docetaxel alone , the combination met the primary endpoint of increasing overall survival ( mean OS , p = 0.03 ; OS log - rank , p < 0.04 ) . It also met key secondary endpoints , including significantly improving ORR , PFS , and 24- and 36 - month OS ( double OS rate vs. docetaxel ) rates , and significant reduction in the incidence of Grade 4 neutropenia . OS rate for 48 months is at 10.6 % for plinabulin + docetaxel vs. 0 % for docetaxel alone . Greater China Partnership on Plinabulin with Hengrui , leading R & D and commercialization company in oncology products in China : Announced an exclusive commercialization and co - development agreement between Jiangsu Hengrui Pharmaceuticals Co. , Ltd. ( or “ Hengrui ” ) and Wanchunbulin , BeyondSpring's China subsidiary , for plinabulin in Greater China , the key terms of which are outlined below :